A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies

Trial Profile

A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Vemurafenib (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jul 2017 Status changed from active, no longer recruiting to recruiting.
    • 10 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top